 |
|
|
| |
Safety, Antiviral Activity, and Pharmacokinetics of a Novel Hepatitis B Virus Capsid Assembly Modulator, JNJ-56136379, in Asian and Caucasian Patients with Chronic Hepatitis B
|
| |
| |
Reported by Jules Levin
EASL 2019 April 10-14 Vienna - home of Gelato
Joris Vandenbossche1, Fabien Zoulim2,3, Oliver Lenz1, Willem Talloen1, Iurie Moscalu4, Mohamed Rosmawati5, Adrian Streinu-Cercel6, Wan-Long Chuang7, Stefan Bourgeois8, Sheng-Shun Yang9, Maria Buti10, Javier Crespo11, Yi-Cheng Chen12, Juan M. Pascasio13, Christoph Sarrazin14, Thomas Vanwolleghem15,16, Umesh Shukla17, John Fry18*, and Jeysen Z. Yogaratnam18
1Janssen Pharmaceutica NV, Beerse, Belgium; 2Croix Rousse Hospital, Hospices Civils de Lyon, Lyon, France; 3INSERM U1052-Cancer Research Institute of Lyon, Lyon, France; 4Spitalul Clinic Republican, Chisinau, Moldova; 5University Malaya Medical Centre, Kuala Lumpur, Malaysia; 6National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; 7Koahsiung Medical University Hospital, Kaohsiung, Taiwan; 8ZNA Jan Palfijn, CPU, Antwerp, Belgium; 9Taichung Veterans General Hospital, Taichung, Taiwan; 10Hospital Universitario Vall d'Hebrón, Barcelona, Spain; 11Hospital Universitario Marques de Valdecilla, Santander, Spain; 12Chang Gang Memorial Hospital LinKou, Taoyuan, Taiwan; 13Hospital Universitario Virgen del Rocio, Seville, Spain; 14Medizinische Klinik II, St. Josefs-Hospital, Weisbaden, Germany; 15Erasmus MC, University Medical Center, Rotterdam, Netherlands; 16Antwerp University Hospital, Antwerp, Belgium; 17Janssen Pharmaceuticals R&D, Titusville, NJ, USA; 18Janssen Biopharma Inc., South San Francisco, CA, USA *J. Fry was employed by Janssen Biopharma at the time of the study and is no longer part of the company
|
| |
|
|
|
|
|
